Thomas W. Flaig

TL;DR: In this article, a 3+3 dose escalation design to determine MTD and RP2D of V 200-400mg QD days (D) 1-14 as an investigational agent with S (400 mg BID D1-21) in 21 D cycles done in patients with advanced malignancies, ECOG PS 0-2 and intact organ function.

TL;DR: Acai juice did not produce enough PSA responses in this patient population to proceed beyond the first stage of this trial, however, PSA doubling time did slow in 85.7% of patients, and the one observed PSA response was sustained over at least 36 weeks at the time of data cutoff.

TL;DR: This is the first reported case of treatment-associated AML after mitoxantrone in prostate cancer, and despite its regular use in this setting, despite aggressive treatment and support, the patient had a rapidly fatal clinical course.

TL;DR: A 43-year-old man who was initially evaluated at an outside institution for unexplained anemia and who was found to have a large right kidney mass underwent a radical nephrectomy for a 19-cm large-cell, poorly differentiated neoplasm consistent with pleomorphic, epithelioid angiomyolipoma (EAML) with extensive necrosis and cytologic atypia.

TL;DR: A post hoc analysis of pts in the AA treatment arm who progressed, characterized subsequent therapy after pts discontinued study drug and found most frequent subsequent therapy was for mCRPC.